EGFR and non-small cell lung carcinoma: Accordingly, anti-PD-L1 therapy induced higher ORRs in PD-L1-positive EGFR mutant patients (31%) compared to EGFR wild-type (22%) NSCLC patients (Peters et al., 2017).